About ReceptoPharm, Inc.

ReceptoPharm, Inc. was incorporated as Receptogen in the United States under the laws of the State of Nevada on June 4, 2001 for the purpose, among other things, of developing and acquiring patents based upon advanced receptor and molecular biology. The name was changed to ReceptoPharm in April of 2003 and the company was licensed to do business in the State of Florida.

ReceptoPharm is engaged in the discovery and development of novel and off-patent peptide technologies primarily for the prevention and treatment of disease in humans. The emphasis of ReceptoPharm's approach to the development of new therapeutic agents is based upon specialized receptor-binding proteins found in nature. ReceptoPharm is focusing on the treatment of viral and neurological diseases.

With its' large volume of research and preclinical data ReceptoPharm believes it has identified a number of therapeutic products that have the capability to provide significant benefits for patients with such diseases as Acquired Immunodeficiency Syndrome (AIDS), Multiple sclerosis, Myasthenia gravis (MG), pain, and other viral disorders. Acknowledging the problems of the currently approved drugs for HIV, ReceptoPharm has selected the development of the HIV/AIDS application as its primary viral indication because of the shorter route to market.

ReceptoPharm's principal executive offices, manufacturing, research and development facilities are located in a single building totaling approximately 5,400 square feet in Plantation, Florida.